Essex Financial Services, Inc.
Position in ALNY — Alnylam Pharmaceuticals, Inc.
CIK 1315785
ESSEX, CT
Position in ALNY
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$260,691
+$26,766 QoQ
Shares Held
866
+22.5% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#565
of 784 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in ALNY Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Essex Financial Services, Inc. holds $1,755,786 across 7 Biotechnology names. ALNY ranks #4 (14.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
840 | $417,253 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
644 | $401,559 | |
| 3 | INCY |
Incyte Corp
|
2,924 | $331,464 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
This page
|
866 | $260,691 | |
| 5 | TGTX |
Tg Therapeutics, Inc.
|
3,748 | $205,915 | |
| 6 | CRMD |
CorMedix Inc.
|
11,835 | $92,904 | |
| 7 | CGTX |
Cognition Therapeutics Inc
|
40,000 | $46,000 |
All Filings in ALNY
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $260,691 | 866 | Shares | Defined | 2026-08-10 | |
| 2026-03-31 | $233,925 | 707 | Shares | Defined | 2026-04-24 | |
| 2025-12-31 | $274,378 | 690 | Shares | Defined | 2026-02-10 | |
| 2025-09-30 | $325,584 | 714 | Shares | Defined | 2025-11-07 | |
| No filing history on record for this holder in this stock. | ||||||